Another Detrimental Effect of Immunosuppression: Metabolic Syndrome

Charles Rickert,James Markmann

DOI: https://doi.org/10.1097/tp.0000000000005253

2024-10-28

Transplantation

Abstract:Modern organ transplantation only exists because of the efficacy of the current immunosuppressive (IS) regimens in wide use. The incredible reduction in rejection rates with the introduction of calcineurin inhibitors and antimetabolites, such as mycophenolic acid, has allowed hundreds of thousands of patients to return to relatively normal lives after transplantation. 1 , 2 However, these agents are also the root of many health challenges that we must address in our posttransplantation patients. Notably, the risk of increased infections has been obvious from the very beginning, and our decades-long experience has also shown us that these medications lead to increases in cancer and organ-specific damage, such as renal injury. Yet, we, as a field, are still finding new issues that develop over time because of these medications. Along these lines, the commendable work by Angelico et al 3 , in this issue of Transplantation , clearly shows the impact of IS exposure on the metabolic health of liver transplant patients and the benefit of limiting IS for these patients.

immunology,surgery,transplantation